Search Results - cb6xxx

11 Results Sort By:
Methods for Using Modulators of Extracellular Adenosine or an Adenosine Receptor To Enhance Immune Response and Inflammation
Local inflammation processes are crucially important in the host defense against pathogens and for successful immunization because proinflammatory cytokines are necessary for initiation and propagation of an immune response. However, normal inflammatory responses are eventually terminated by physiological termination mechanisms, thereby limiting the...
Published: 10/28/2024   |   Inventor(s): Akio Ohta, Michail Sitkovsky
Keywords(s): 2IXXXX, 2JXXXX, CB3CXX, CB6XXX, Controlling, DC1XXX, IA3XXX, Inflammation, Listed LPM Thalhammer-Reyero as of 4/15/2015, Method, Patent Category - Chemistry, Post LPM Assignment Set 20150420, Pre LPM working set 20150418
Category(s): TherapeuticArea > Immunology, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease, Application > Diagnostics, Application > Therapeutics, Application > Vaccines
T Cell-Based Adoptive Transfer Immunotherapy for Polyomavirus-Associated Pathologies
Available for licensing are methods to generate T cells responsive to multiple polyomaviruses. The resulting T cell populations could be useful in treating immunosuppressed individuals with polyomavirus infections or polyomavirus-associated pathologies such as Merkel cell carcinoma (MCC), polyomavirus-associated nephropathy (PVAN), hemorrhagic cystitis,...
Published: 10/28/2024   |   Inventor(s): Dhanalakshmi (Donna) Chinnasamy, Pawel Muranski, Christopher Buck, John Barrett
Keywords(s): adoptive transfer, BKV, CB2AXX, CB6XXX, Immunotherapy, Merkel, MKV, Patent Category - Biotechnology, Polyoma, polyomavirus, viral, virus, VLXXXX, WJXXXX, XAXXXX, XEXXXX, YAXXXX, YBXXXX
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Immunology, ResearchProducts > Antibodies, Application > Therapeutics, TherapeuticArea > Infectious Disease, TherapeuticArea > Oncology
Modulation of Leucine-rich Repeats and Calponin Homology Domain-containing Protein 4 (Lrch4) Activity for Therapeutic Applications
NIH Inventors have recently discovered a novel Leucine-rich repeat and calponin homology domain-containing protein 4 (Lrch4) in a proteomic screen of the plasma membrane of lipopolysaccharide (LPS)-exposed macrophages. Expression data by RT-PCR revealed that all Lrch family members (1-4) are expressed in macrophages, but only Lrch4 was recruited into...
Published: 10/28/2024   |   Inventor(s): Michael Fessler
Keywords(s): CB6XXX, CBXXXX, CXXXXX, DISEASES, GB1XXX, GBXXXX, GXXXXX, IB3XXX, IBXXXX, INFLAMMATORY, IXXXXX, Lrch4, Sepsis, TARGET, therapeutic
Category(s): Collaboration Sought > Collaboration, Application > Research Materials, Application > Diagnostics, Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Immunology
Novel Therapeutic Compounds for Treatment of Cancer and Immune Disorders
The global market for cancer therapeutics is over $40 billion and is anticipated to continue to rise in the future. There remains a significant unmet need for therapeutics for cancers that affect blood, bone marrow, and lymph nodes and the immune system, such as leukemia, multiple myeloma, and lymphoma. The proteasome inhibitor bortezomib, which may...
Published: 10/28/2024   |   Inventor(s): Yihong Ye, William Trenkle, Adrian Wiestner
Keywords(s): anti-cancer, Bortezomib, CANCER, CB5AXX, CB5EXX, CB5XXX, CB6XXX, CBXXXX, CXXXXX, DB4AXX, DB4XXX, DBXXXX, Diacyl, DXXXXX, ERAD, Hematologic, HYDRAZINE, Hydrazone, immunosuppressant, inhibitor, Patent Category - Chemistry, Proteasome, Proteasome inhibitor, retroviral, tumor
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology
Methods for Treating or Ameliorating Fibrosis by Inhibiting the Interaction between IL-21 Receptor (IL-21R) and IL-21
This invention includes methods for treating or ameliorating fibrosis by inhibiting the interaction between IL-21 Receptor (IL-21R) and IL-21 using either anti-IL-21R monoclonal antibodies (or binding fragments of anti-IL-21R mAbs), anti-IL-21 monoclonal antibodies (or binding fragments of anti-IL-21 mAbs) or soluble IL-21R (or binding fragments of...
Published: 10/28/2024   |   Inventor(s): Thomas Wynn
Keywords(s): Asbestosis, CB1AXX, CB1XXX, CB6XXX, CBXXXX, CXXXXX, Cystic fibrosis, DEFICIENCY, FIBROSIS, Hepatitis A, Hepatitis D, Hepatitis E, IL-21, Immunity, Inflammmation, Patent Category - Biotechnology, RECEPTOR, REDUCES, SCHISTOSOMIASIS, Schistosomiasis (Schistosoma sp.), Scleroderma, Scleroderma, systemic, Tissue, TYPE-2
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Immunology, TherapeuticArea > Oncology, Application > Therapeutics
Methods for Expression and Purification of Immunotoxins
The invention concerns immunotoxins and methods of making the immunotoxins. Targeting of the immunotoxins occurs via an antibody that is specific to T cells. This allows the specific ablation of malignant T cells and resting T cells. The transient ablation of resting T cells can "reset" the immune system by accentuating tolerizing responses. As...
Published: 10/28/2024   |   Inventor(s): David Neville
Keywords(s): Aplastic anemia, Are, Bivalent, CB6XXX, CBXXXX, COMPLEX, CXXXXX, ESSENTIAL, Graft versus host disease, IB3XXX, IBXXXX, Immunotoxin, IXXXXX, LOW, lymphoma, Media, PASTORIS, PICHIA, production, temperature
Category(s): Collaboration Sought > Licensing, Application > Research Materials, TherapeuticArea > Immunology, Application > Diagnostics, Application > Therapeutics, TherapeuticArea > Oncology
Diagnostic and Therapeutic Use of Brother of the Regulator of Imprinted Sites (BORIS) Alternative Splice Forms
This technology identifies twenty five (25) new alternatively spliced transcripts of the BORIS gene. The transcripts lead to the expression of seventeen different protein isoforms with variable N- and C-termini encoded by BORIS gene locus. Differential expression levels of BORIS isoforms were observed in different cancers. While some BORIS alternative...
Published: 10/28/2024   |   Inventor(s): Victor Lobanenkov
Keywords(s): Alternate, Boris, CA1AXX, CA1XXX, CANCER, CAXXXX, CB6XXX, CBXXXX, CXXXXX, Diagnostics, Forms, MULTIPLE, SPLICE, Tool, treatment
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Therapeutics, Application > Diagnostics
Enriched Natural Killer Cells for Adoptive Infusion Cancer Therapy
Immuno-therapy has taken a lead among the new cancer therapeutic approaches. It is one of the most promising new therapeutic approaches that exploit the innate immune mechanism of an individual to fight against a certain disease. Natural killer (NK) cells are a form of cytotoxic lymphocytes which constitute a major portion of the innate immune system....
Published: 10/28/2024   |   Inventor(s): Richard Childs
Keywords(s): 47 XYY syndrome, BBXXXX, CB6XXX, CBXXXX, CXXXXX, Double Y
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Therapeutics
ARH3, a Therapeutic Target for Cancer, Ischemia, and Inflammation
ADP-ribosylation is important in many cellular processes, including DNA replication and repair, maintenance of genomic stability, telomere dynamics, cell differentiation and proliferation, and necrosis and apoptosis. Poly-ADP-ribose is important in a number of critical physiological processes such as DNA repair, cellular differentiation, and carcinogenesis....
Published: 10/28/2024   |   Inventor(s): Joel Moss
Keywords(s): Activity, Alpha-NAD, Alpha-NADase, ARH3, CB6XXX, CBXXXX, Cell, CXXXXX, Enzyme, Hydrolase:, IB6XXX, IBXXXX, Ihe, IXXXXX, LEVELS, Maintenance, MAMMALIAN, MAY, PAR, PARG-like, Patent Category - Biotechnology, Poly-ADP-ribose, RELEVANT
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Vaccines, Application > Therapeutics, TherapeuticArea > Immunology, TherapeuticArea > Oncology, TherapeuticArea > Reproductive Health, Application > Diagnostics, Application > Research Materials
Identification of Candidate Ligands which Modulate Antigen Presenting Cells
Available for licensing and commercial development are novel biotechnological tools, prophylactics, therapeutics, and methods for modulating the activation state of an antigen presenting cell (APC) and thereby modulating the activation of a killer T cell. The activation of a killer T cell can occur in a two cell complex and two sequential steps: a)...
Published: 10/28/2024   |   Inventor(s): Polly Matzinger, John Ridge
Keywords(s): CB6XXX, CBXXXX, CXXXXX, DB4XXX, DBXXXX, DC5XXX, DCXXXX, DXXXXX, IB3XXX, IBXXXX, IXXXXX
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Immunology, Application > Diagnostics, Application > Research Materials, Application > Therapeutics, Application > Vaccines, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease
1 2